Background
IFM 2009 was a phase III randomized open-label trial addressing whether early (upfront) autologous stem cell transplantation (ASCT) remains necessary in the era of novel agent induction, specifically bortezomib-lenalidomide-dexamethasone (VRd). Prior randomized trials (IFM 96-01, EBMT) had established ASCT superiority over older chemotherapy, but no randomized data existed comparing ASCT to a modern triplet regimen. IFM 2009 directly tested whether VRd alone (8 cycles) was equivalent to VRd induction followed by ASCT and VRd consolidation, both followed by lenalidomide maintenance.
Interventions and follow up
Arm A (no ASCT): VRd × 8 cycles (induction + consolidation, no ASCT) → lenalidomide maintenance × 1 year
Arm B (ASCT): VRd × 3 induction cycles → high-dose melphalan + ASCT → VRd × 2 consolidation cycles → lenalidomide maintenance × 1 year
Primary endpoint: Progression-free survival (PFS)
Secondary: OS, complete response (CR) rate, MRD negativity (10⁻⁴)
mFollow-up: 44 months
Arm B (ASCT): VRd × 3 induction cycles → high-dose melphalan + ASCT → VRd × 2 consolidation cycles → lenalidomide maintenance × 1 year
Primary endpoint: Progression-free survival (PFS)
Secondary: OS, complete response (CR) rate, MRD negativity (10⁻⁴)
mFollow-up: 44 months
Results
mPFS: 50.0 months (ASCT) vs 36.0 months (no ASCT) (HR 0.65, 95% CI 0.53–0.80, P<.001)
4-yr OS: 81.2% vs 82.6% (HR 1.16, not significant)
CR: 58.9% vs 48.5% (P=.003)
MRD negativity (10⁻⁴): 79% vs 65% (P<.001)
Salvage ASCT: 35% of Arm A patients received salvage ASCT at progression
4-yr OS: 81.2% vs 82.6% (HR 1.16, not significant)
CR: 58.9% vs 48.5% (P=.003)
MRD negativity (10⁻⁴): 79% vs 65% (P<.001)
Salvage ASCT: 35% of Arm A patients received salvage ASCT at progression
Adverse events
Hematologic: Grade ≥3 hematologic AEs higher in ASCT arm (expected post-melphalan)
Infectious/GI: ASCT arm higher Grade 3–4 infections and mucositis early (melphalan-related)
Non-hematologic: Grade ≥3 non-hematologic AEs comparable between arms; peripheral neuropathy 8% vs 8% Grade ≥3 (VRd comparable); no transplant-related mortality difference reported
Infectious/GI: ASCT arm higher Grade 3–4 infections and mucositis early (melphalan-related)
Non-hematologic: Grade ≥3 non-hematologic AEs comparable between arms; peripheral neuropathy 8% vs 8% Grade ≥3 (VRd comparable); no transplant-related mortality difference reported
Conclusions
Upfront ASCT after VRd induction significantly prolonged PFS (50 vs 36 months, HR 0.65) and deepened responses (CR and MRD negativity) compared to VRd alone without ASCT, reaffirming ASCT as the standard of care for transplant-eligible NDMM in the era of novel agents, though OS was not improved, likely due to effective salvage ASCT at relapse.
Key Limitations
Maintenance was only 1 year in both arms (non-indefinite) — current practice uses indefinite lenalidomide maintenance; salvage ASCT crossover in 35% of the no-ASCT arm mitigates OS difference and limits interpretation; VRd used as induction was triplet (not quadruplet) — contemporary standard has moved to D-VRd (PERSEUS); OS equivalence has led some to argue delayed ASCT is acceptable for select patients; IFM trial was French (European centers) — no US-based trial directly replicates this; shorter maintenance limits generalizability to modern practice.
Clinical Context
IFM 2009 settled the debate about whether early ASCT was still necessary with modern VRd induction, reaffirming its role for PFS benefit even though OS was equivalent. The contemporaneous DETERMINATION trial (NEJM 2022, Richardson PG) similarly showed PFS advantage for early ASCT (mPFS 67.5 vs 46.2 months with indefinite lenalidomide maintenance) but no OS benefit in US patients with indefinite maintenance. Together these trials confirm: early ASCT prolongs PFS but OS equivalence can be maintained with delayed ASCT. Early ASCT is the preferred standard for eligible patients per ASCO/ESMO guidance. Quadruplet D-VRd induction (PERSEUS) now precedes ASCT in contemporary practice.